Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CalciMedica, Inc.CALC · Entity 7804 | Director · CHIEF BUSINESS OFFICER | August 19, 2026 | August 21, 2026 |
| VIVUS INCVVUS · Entity 151460 | Director | February 28, 2019 | March 04, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CalciMedica, Inc.
Report date August 19, 2026 · Filed August 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $0.80 · Expires 2027-12-25 | Direct | 186,729 |
Reported balance
After 2026-08-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-19 · Grant · Acquired 186,729 · Balance 186,729 F1: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. F2: The warrant may be exercised on or after August 19, 2026, and on or prior to the earlier of (i) December 25, 2027 and (ii) thirty (30) days following the Issuer's public disclosure of the clearance of its Investigational New Drug Application by the U.S. Food and Drug Administration for CM5480; provided, however, that the holder will be prohibited, subject to certain exceptions, from exercising such warrant for shares of common stock of the Issuer to the extent that immediately prior to or after giving effect to such exercise, the holder, together with its affiliates and other attribution parties, would own more than 19.99% of the total number of shares of common stock of the Issuer then issued and outstanding, which percentage may be changed at the holder's election to a lower percentage at any time or to a higher percentage upon 61 days' notice to the Issuer. |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $1.00 · Expires 2031-06-25 | Direct | 186,729 |
Reported balance
After 2026-08-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-19 · Grant · Acquired 186,729 · Balance 186,729 F1: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. F3: The warrant may be exercised on or after August 19, 2026 and on or prior to June 25, 2031; provided, however, that the holder will be prohibited, subject to certain exceptions, from exercising such warrant for shares of common stock of the Issuer to the extent that immediately prior to or after giving effect to such exercise, the holder, together with its affiliates and other attribution parties, would own more than 19.99% of the total number of shares of common stock of the Issuer then issued and outstanding, which percentage may be changed at the holder's election to a lower percentage at any time or to a higher percentage upon 61 days' notice to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.
F2: The warrant may be exercised on or after August 19, 2026, and on or prior to the earlier of (i) December 25, 2027 and (ii) thirty (30) days following the Issuer's public disclosure of the clearance of its Investigational New Drug Application by the U.S. Food and Drug Administration for CM5480; provided, however, that the holder will be prohibited, subject to certain exceptions, from exercising such warrant for shares of common stock of the Issuer to the extent that immediately prior to or after giving effect to such exercise, the holder, together with its affiliates and other attribution parties, would own more than 19.99% of the total number of shares of common stock of the Issuer then issued and outstanding, which percentage may be changed at the holder's election to a lower percentage at any time or to a higher percentage upon 61 days' notice to the Issuer.
F3: The warrant may be exercised on or after August 19, 2026 and on or prior to June 25, 2031; provided, however, that the holder will be prohibited, subject to certain exceptions, from exercising such warrant for shares of common stock of the Issuer to the extent that immediately prior to or after giving effect to such exercise, the holder, together with its affiliates and other attribution parties, would own more than 19.99% of the total number of shares of common stock of the Issuer then issued and outstanding, which percentage may be changed at the holder's election to a lower percentage at any time or to a higher percentage upon 61 days' notice to the Issuer.
VIVUS INC
Report date February 28, 2019 · Filed March 04, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,660 |
Reported balance
After 2019-02-28 transaction · row 1
1 source rowRow 1 · 2019-02-28 · Purchase · Acquired 8,500 · Balance 16,660 F1: This is the weighted average purchase price. Shares were purchased in multiple transactions at prices from $4.78 to $4.8998. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4. The amount reflected has been rounded to 4 decimal points. |
Filing footnotes · ownership attribution and instrument terms
F1: This is the weighted average purchase price. Shares were purchased in multiple transactions at prices from $4.78 to $4.8998. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4. The amount reflected has been rounded to 4 decimal points.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Invuity, Inc.
Report date October 23, 2018 · Filed October 23, 2018
Section 16 reporting ended · disclosed 2018-10-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2018-10-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-10-23 · Disposition to issuer · Disposed 163,795 · Balance 34,246 F1: Disposed of pursuant to that certain Agreement and Plan of Merger between the Issuer, Stryker Corporation and Accipiter Corp., dated as of September 10, 2018 (the "Merger Agreement"), in exchange for a cash payment of $7.40 per share, without interest, subject to any required withholding of taxes (the "Offer Price"). Row 2 · 2018-10-23 · Disposition to issuer · Disposed 34,246 · Balance 0 F2: These securities were restricted stock units ("RSUs"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. F3: The RSUs were cancelled pursuant to the Merger Agreement in exchange for an amount in cash per underlying share equal to the Offer Price. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.87 · Expires 2021-05-19 | Direct | 0 |
Reported balance
After 2018-10-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-10-23 · Disposition to issuer · Disposed 28,900 · Balance 0 F4: The option was cancelled pursuant to the Merger Agreement in exchange for an amount in cash equal to the product of (a) the excess of the Offer Price over the per-share exercise price of such option multiplied by (b) the number of unexercised shares subject to such option. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to that certain Agreement and Plan of Merger between the Issuer, Stryker Corporation and Accipiter Corp., dated as of September 10, 2018 (the "Merger Agreement"), in exchange for a cash payment of $7.40 per share, without interest, subject to any required withholding of taxes (the "Offer Price").
F2: These securities were restricted stock units ("RSUs"), each of which represented a contingent right to receive one share of the Issuer's Common Stock.
F3: The RSUs were cancelled pursuant to the Merger Agreement in exchange for an amount in cash per underlying share equal to the Offer Price.
F4: The option was cancelled pursuant to the Merger Agreement in exchange for an amount in cash equal to the product of (a) the excess of the Offer Price over the per-share exercise price of such option multiplied by (b) the number of unexercised shares subject to such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 23, 2023 Filed Jun 27, 2023 00:33 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 500 | $3.35 | $1,675.00 |
DisclosureSEC source: 0001209191-23-039831 · doc4.xml · nonDerivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Oppenheimer & Co Inc. Custodian FBO Eric W Roberts Roth IRA Disclosed balance after: 16,185 Read SEC document |
| June 21, 2023 Filed Jun 22, 2023 23:31 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 2,000 | $4.13 | $8,250.00 |
DisclosureSEC source: 0001209191-23-039176 · doc4.xml · nonDerivative · entry 2 Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Oppenheimer & Co Inc. Custodian FBO Eric W Roberts Roth IRA Disclosed balance after: 15,685 F1 · price: The weighted average purchase price for the transaction reported was $4.125, and the range of prices were between $3.95 and $4.35. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| June 20, 2023 Filed Jun 22, 2023 23:31 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 500 | $4.85 | $2,425.00 |
DisclosureSEC source: 0001209191-23-039176 · doc4.xml · nonDerivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Oppenheimer & Co Inc. Custodian FBO Eric W Roberts Roth IRA Disclosed balance after: 13,685 Read SEC document |
| June 08, 2023 Filed Jun 10, 2023 01:17 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 485 | $5.20 | $2,522.00 |
DisclosureSEC source: 0001209191-23-036128 · doc4.xml · nonDerivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Oppenheimer & Co Inc. Custodian FBO Eric W Roberts Roth IRA Disclosed balance after: 13,185 Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 01:10 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 1,500 | $5.23 | $7,840.05 |
DisclosureSEC source: 0001209191-23-035612 · doc4.xml · nonDerivative · entry 2 Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Oppenheimer & Co Inc. Custodian FBO Eric W Roberts Roth IRA Disclosed balance after: 12,700 F1 · price: The weighted average purchase price for the transaction reported was $5.2267, and the range of prices were between $5.20 and $5.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| June 06, 2023 Filed Jun 9, 2023 01:10 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 3,200 | $5.09 | $16,278.40 |
DisclosureSEC source: 0001209191-23-035612 · doc4.xml · nonDerivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Oppenheimer & Co Inc. Custodian FBO Eric W Roberts Roth IRA Disclosed balance after: 11,200 F1 · price: The weighted average purchase price for the transaction reported was $5.2267, and the range of prices were between $5.20 and $5.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| June 02, 2023 Filed Jun 5, 2023 23:20 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 1,687 | $4.90 | $8,266.30 |
DisclosureSEC source: 0001209191-23-034639 · doc4.xml · nonDerivative · entry 2 Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,187 F2 · price: The weighted average purchase price for the transaction reported was $4.9, and the range of prices were between $4.97628 and $4.9. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 23:20 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 2,000 | $4.42 | $8,830.00 |
DisclosureSEC source: 0001209191-23-034639 · doc4.xml · nonDerivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,500 F1 · price: The weighted average purchase price for the transaction reported was $4.415, and the range of prices were between $4.37 and $4.43. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| May 30, 2023 Filed Jun 1, 2023 23:46 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 2,000 | $3.86 | $7,723.20 |
DisclosureSEC source: 0001209191-23-033459 · doc4.xml · nonDerivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Oppenheimer & Co Inc. Custodian FBO Eric W Roberts Roth IRA Disclosed balance after: 8,000 Read SEC document |
| May 23, 2023 Filed May 25, 2023 00:13 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 2,000 | $3.26 | $6,526.00 |
DisclosureSEC source: 0001209191-23-032023 · doc4.xml · nonDerivative · entry 2 Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,500 F1 · price: The weighted average purchase price for the transaction reported was $3.263, and the range of prices were between $3.25 and $3.276. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| May 22, 2023 Filed May 25, 2023 00:13 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 6,000 | $2.95 | $17,700.00 |
DisclosureSEC source: 0001209191-23-032023 · doc4.xml · nonDerivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Oppenheimer & Co Inc. Custodian FBO Eric W Roberts Roth IRA Disclosed balance after: 6,000 Read SEC document |
| May 17, 2023 Filed May 18, 2023 22:05 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 3,000 | $2.68 | $8,040.00 |
DisclosureSEC source: 0001209191-23-030779 · doc4.xml · nonDerivative · entry 2 Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,500 Read SEC document |
| May 17, 2023 Filed Nov 7, 2024 01:00 UTC Amendment | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 3,000 | $2.68 | $8,040.00 |
DisclosureSEC source: 0001415889-24-026280 · form4a-11062024_081102.xml · nonDerivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Oppenheimer & Co Inc. Custodian FBO Eric W Roberts Roth IRA Disclosed balance after: 3,000 F1 · balance_after: On May 18, 2023, the Reporting Person filed a Form 4 which inadvertently omitted the purchase of 3,000 shares of the Issuer's common stock by Oppenheimer & Co Inc. Custodian FBO Eric W Roberts Roth IRA (the "Oppenheimer IRA"). In fact, as reported in this amendment, the Reporting Person indirectly owned 3,000 shares of common stock held by the Oppenheimer IRA following the purchase. Read SEC document |
| May 16, 2023 Filed May 18, 2023 22:05 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 1,800 | $2.72 | $4,896.00 |
DisclosureSEC source: 0001209191-23-030779 · doc4.xml · nonDerivative · entry 3 Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By FMTC Custodian - Roth IRA FBO Eric W. Roberts Disclosed balance after: 1,800 F2 · price: The weighted average purchase price for the transaction reported was $2.71, and the range of prices were between $2.65 and $2.75. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| May 16, 2023 Filed May 18, 2023 22:05 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 3,500 | $2.71 | $9,485.00 |
DisclosureSEC source: 0001209191-23-030779 · doc4.xml · nonDerivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,500 F1 · price: The weighted average purchase price for the transaction reported was $2.72, and the range of prices were between $2.60 and $2.76. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| May 08, 2023 Filed May 10, 2023 22:21 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (Right to Buy) · Derivative | 60,709 | $0.00 Strike: $3.25 | $0.00 |
DisclosureSEC source: 0001209191-23-028552 · doc4.xml · derivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,709 Underlying: Common Stock · 60,709 shares Expires 2033-05-07 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest in equal monthly installments over a four year period following the date of grant. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:50 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantWarrant · Derivative | 9,935 | Not disclosed Strike: $27.94 | Not disclosed |
DisclosureSEC source: 0001209191-23-020680 · doc4.xml · derivative · entry 19 Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Valence Investments SPV V, LLC Disclosed balance after: 9,935 Underlying: Common Stock · 9,935 shares Expires 2026-06-25 F26 · price: Received in exchange for a stock option to acquire 344,934 shares of common stock of CalciMedica pursuant to the Merger Agreement. F14 · derivative.exercise_date: Immediately exercisable. F2 · ownership.nature: The Reporting Person, a co-founder and managing director of Valence Investments SPV IV, LLC ("Valence IV"), Valence Investments SPV V, LLC ("Valence V") and Valence Investments SPV VI, LLC (Valence VI), may be deemed to beneficially own the securities held by Valence IV, Valence V and Valence VI (the "Valence Securities"). The Reporting Person disclaims beneficial ownership of the Valence Securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:50 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantWarrant · Derivative | 9,935 | Not disclosed Strike: $27.94 | Not disclosed |
DisclosureSEC source: 0001209191-23-020680 · doc4.xml · derivative · entry 18 Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Valence Investments SPV V, LLC Disclosed balance after: 9,935 Underlying: Common Stock · 9,935 shares Expires 2026-02-22 F26 · price: Received in exchange for a stock option to acquire 344,934 shares of common stock of CalciMedica pursuant to the Merger Agreement. F14 · derivative.exercise_date: Immediately exercisable. F2 · ownership.nature: The Reporting Person, a co-founder and managing director of Valence Investments SPV IV, LLC ("Valence IV"), Valence Investments SPV V, LLC ("Valence V") and Valence Investments SPV VI, LLC (Valence VI), may be deemed to beneficially own the securities held by Valence IV, Valence V and Valence VI (the "Valence Securities"). The Reporting Person disclaims beneficial ownership of the Valence Securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:50 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantWarrant · Derivative | 2,793 | Not disclosed Strike: $10.42 | Not disclosed |
DisclosureSEC source: 0001209191-23-020680 · doc4.xml · derivative · entry 17 Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,793 Underlying: Common Stock · 2,793 shares Expires 2031-04-27 F25 · price: Received in exchange for a warrant to purchase 96,970 shares of common stock of CalciMedica pursuant to the Merger Agreement. F24 · derivative.exercise_date: Beginning on February 22, 2021, the shares subject to the warrant shall be exercisable in a series of forty-eight (48) successive equal monthly installments. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:50 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (right to buy) · Derivative | 1,804 | Not disclosed Strike: $17.34 | Not disclosed |
DisclosureSEC source: 0001209191-23-020680 · doc4.xml · derivative · entry 16 Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,804 Underlying: Common Stock · 1,804 shares Expires 2023-03-19 F10 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. F23 · price: Received in exchange for a stock option to acquire 62,659 shares of common stock of CalciMedica pursuant to the Merger Agreement. F20 · derivative.exercise_date: Beginning on November 22, 2022, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:50 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (right to buy) · Derivative | 20,060 | Not disclosed Strike: $17.34 | Not disclosed |
DisclosureSEC source: 0001209191-23-020680 · doc4.xml · derivative · entry 15 Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,060 Underlying: Common Stock · 20,060 shares Expires 2033-03-19 F10 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. F22 · price: Received in exchange for a stock option to acquire 696,547 shares of common stock of CalciMedica pursuant to the Merger Agreement. F20 · derivative.exercise_date: Beginning on November 22, 2022, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:50 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (right to buy) · Derivative | 5,284 | Not disclosed Strike: $17.34 | Not disclosed |
DisclosureSEC source: 0001209191-23-020680 · doc4.xml · derivative · entry 14 Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,284 Underlying: Common Stock · 5,284 shares Expires 2033-03-19 F10 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. F21 · price: Received in exchange for a stock option to acquire 183,501 shares of common stock of CalciMedica pursuant to the Merger Agreement. F20 · derivative.exercise_date: Beginning on November 22, 2022, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:50 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (right to buy) · Derivative | 1,263 | Not disclosed Strike: $10.42 | Not disclosed |
DisclosureSEC source: 0001209191-23-020680 · doc4.xml · derivative · entry 13 Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,263 Underlying: Common Stock · 1,263 shares Expires 2032-08-30 F10 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. F19 · price: Received in exchange for a stock option to acquire 43,873 shares of common stock of CalciMedica pursuant to the Merger Agreement. F14 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:50 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (right to buy) · Derivative | 1,677 | Not disclosed Strike: $10.42 | Not disclosed |
DisclosureSEC source: 0001209191-23-020680 · doc4.xml · derivative · entry 12 Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,677 Underlying: Common Stock · 1,677 shares Expires 2032-08-30 F10 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. F18 · price: Received in exchange for a stock option to acquire 58,235 shares of common stock of CalciMedica pursuant to the Merger Agreement. F14 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:50 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (right to buy) · Derivative | 2,935 | Not disclosed Strike: $10.42 | Not disclosed |
DisclosureSEC source: 0001209191-23-020680 · doc4.xml · derivative · entry 11 Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,935 Underlying: Common Stock · 2,935 shares Expires 2032-08-30 F10 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. F17 · price: Received in exchange for a stock option to acquire 101,911 shares of common stock of CalciMedica pursuant to the Merger Agreement. F14 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:50 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (right to buy) · Derivative | 11,778 | Not disclosed Strike: $7.99 | Not disclosed |
DisclosureSEC source: 0001209191-23-020680 · doc4.xml · derivative · entry 10 Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,778 Underlying: Common Stock · 11,778 shares Expires 2031-06-30 F16 · price: Received in exchange for a stock option to acquire 408,982 shares of common stock of CalciMedica pursuant to the Merger Agreement. F12 · derivative.exercise_date: Beginning on February 22, 2021, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:50 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (right to buy) · Derivative | 6,982 | Not disclosed Strike: $7.99 | Not disclosed |
DisclosureSEC source: 0001209191-23-020680 · doc4.xml · derivative · entry 9 Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,982 Underlying: Common Stock · 6,982 shares Expires 2031-06-30 F10 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. F13 · price: Received in exchange for a stock option to acquire 242,431 shares of common stock of CalciMedica pursuant to the Merger Agreement. F12 · derivative.exercise_date: Beginning on February 22, 2021, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:50 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (right to buy) · Derivative | 11,739 | Not disclosed Strike: $7.99 | Not disclosed |
DisclosureSEC source: 0001209191-23-020680 · doc4.xml · derivative · entry 8 Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,739 Underlying: Common Stock · 11,739 shares Expires 2031-04-27 F10 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. F15 · price: Received in exchange for a stock option to acquire 408,982 shares of common stock of CalciMedica pursuant to the Merger Agreement. F14 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:50 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (right to buy) · Derivative | 6,982 | Not disclosed Strike: $7.99 | Not disclosed |
DisclosureSEC source: 0001209191-23-020680 · doc4.xml · derivative · entry 7 Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,982 Underlying: Common Stock · 6,982 shares Expires 2031-04-27 F10 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. F13 · price: Received in exchange for a stock option to acquire 242,431 shares of common stock of CalciMedica pursuant to the Merger Agreement. F12 · derivative.exercise_date: Beginning on February 22, 2021, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:50 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (right to buy) · Derivative | 36,041 | Not disclosed Strike: $6.60 | Not disclosed |
DisclosureSEC source: 0001209191-23-020680 · doc4.xml · derivative · entry 6 Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,041 Underlying: Common Stock · 36,041 shares Expires 2030-06-29 F10 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. F11 · price: Received in exchange for a stock option to acquire 1,251,440 shares of common stock of CalciMedica pursuant to the Merger Agreement. F9 · derivative.exercise_date: 25% of the shares subject to the option vested on May 20, 2020 and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments thereafter. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:50 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (right to buy) · Derivative | 22,851 | Not disclosed Strike: $6.60 | Not disclosed |
DisclosureSEC source: 0001209191-23-020680 · doc4.xml · derivative · entry 5 Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,851 Underlying: Common Stock · 22,851 shares Expires 2030-01-23 F8 · price: Received in exchange for a stock option to acquire 793,470 shares of common stock of CalciMedica pursuant to the Merger Agreement. F6 · derivative.exercise_date: 25% of the shares subject to the option vested on April 30, 2020 and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments thereafter. F7 · derivative.exercise_date: 25% of the shares subject to the option vested on May 20, 2021 and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments thereafter. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:50 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantCommon Stock | 10,661 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-020680 · doc4.xml · nonDerivative · entry 4 Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By IRA Financial Trust Company CFBO Eric W. Roberts Disclosed balance after: 10,661 F5 · price: Received in exchange for 370,140 shares of the common stock of CalciMedica pursuant to the Merger Agreement. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:50 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantCommon Stock | 316,109 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-020680 · doc4.xml · nonDerivative · entry 3 Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Valence Investments SPV VI, LLC Disclosed balance after: 316,109 F4 · price: Received in exchange for 10,975,977 shares of the common stock of CalciMedica pursuant to the Merger Agreement. F2 · ownership.nature: The Reporting Person, a co-founder and managing director of Valence Investments SPV IV, LLC ("Valence IV"), Valence Investments SPV V, LLC ("Valence V") and Valence Investments SPV VI, LLC (Valence VI), may be deemed to beneficially own the securities held by Valence IV, Valence V and Valence VI (the "Valence Securities"). The Reporting Person disclaims beneficial ownership of the Valence Securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:50 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantCommon Stock | 66,228 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-020680 · doc4.xml · nonDerivative · entry 2 Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Valence Investments SPV V, LLC Disclosed balance after: 66,228 F3 · price: Received in exchange for 2,299,564 shares of the common stock of CalciMedica pursuant to the Merger Agreement. F2 · ownership.nature: The Reporting Person, a co-founder and managing director of Valence Investments SPV IV, LLC ("Valence IV"), Valence Investments SPV V, LLC ("Valence V") and Valence Investments SPV VI, LLC (Valence VI), may be deemed to beneficially own the securities held by Valence IV, Valence V and Valence VI (the "Valence Securities"). The Reporting Person disclaims beneficial ownership of the Valence Securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:50 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantCommon Stock | 356,989 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-020680 · doc4.xml · nonDerivative · entry 1 Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Valence Investments SPV IV, LLC Disclosed balance after: 356,989 F1 · price: Received in exchange for an aggregate of 12,395,423 shares of common stock of CalciMedica, Inc. ("CalciMedica") pursuant to an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") by and among CalciMedica, the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"). Under the terms of the Merger Agreement, on March 20, 2023, Merger Sub merged with and into CalciMedica (the "Merger"), with CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. F2 · ownership.nature: The Reporting Person, a co-founder and managing director of Valence Investments SPV IV, LLC ("Valence IV"), Valence Investments SPV V, LLC ("Valence V") and Valence Investments SPV VI, LLC (Valence VI), may be deemed to beneficially own the securities held by Valence IV, Valence V and Valence VI (the "Valence Securities"). The Reporting Person disclaims beneficial ownership of the Valence Securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 16:45 UTC | VIVUS INC VVUS · Entity 151460 | PurchaseCommon Stock | 8,500 | $4.82 | $40,981.90 |
DisclosureSEC source: 0001123292-19-000416 · edgar.xml · nonDerivative · entry 1 Roberts Eric W · CIK 0001576244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,660 F1 · price: This is the weighted average purchase price. Shares were purchased in multiple transactions at prices from $4.78 to $4.8998. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4. The amount reflected has been rounded to 4 decimal points. Read SEC document |
| October 26, 2018 Filed Oct 29, 2018 19:57 UTC | VIVUS INC VVUS · Entity 151460 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $3.53 | $0.00 |
DisclosureSEC source: 0001123292-18-001046 · edgar.xml · derivative · entry 1 Roberts Eric W · CIK 0001576244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires not disclosed F1 · derivative.exercise_date: One twelfth (1/12th) of the total number of shares underlying the option vest and become exercisable on the 26th of each month following October 26, 2018, subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2018 Equity Incentive Plan) on the relevant vesting dates. F2 · derivative.expiration_date: The option expires on the earlier of (a) October 26, 2025 and (b) the six (6) month anniversary of the date the reporting person ceases to be a Service Provider. Read SEC document |
| October 23, 2018 Filed Oct 23, 2018 17:42 UTC | Invuity, Inc. IVTY · Entity 162847 | Disposition to issuerDirector Stock Option (right to buy) · Derivative | 28,900 | $0.00 Strike: $4.87 | $0.00 |
DisclosureSEC source: 0001209191-18-055987 · doc4.xml · derivative · entry 3 Roberts Eric W · CIK 0001576244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,900 shares Expires 2021-05-19 F4 · derivative.exercise_date: The option was cancelled pursuant to the Merger Agreement in exchange for an amount in cash equal to the product of (a) the excess of the Offer Price over the per-share exercise price of such option multiplied by (b) the number of unexercised shares subject to such option. Read SEC document |
| October 23, 2018 Filed Oct 23, 2018 17:42 UTC | Invuity, Inc. IVTY · Entity 162847 | Disposition to issuerCommon Stock | 34,246 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-055987 · doc4.xml · nonDerivative · entry 2 Roberts Eric W · CIK 0001576244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: These securities were restricted stock units ("RSUs"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. F3 · price: The RSUs were cancelled pursuant to the Merger Agreement in exchange for an amount in cash per underlying share equal to the Offer Price. Read SEC document |
| October 23, 2018 Filed Oct 23, 2018 17:42 UTC | Invuity, Inc. IVTY · Entity 162847 | Disposition to issuerCommon Stock | 163,795 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-055987 · doc4.xml · nonDerivative · entry 1 Roberts Eric W · CIK 0001576244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,246 F1 · price: Disposed of pursuant to that certain Agreement and Plan of Merger between the Issuer, Stryker Corporation and Accipiter Corp., dated as of September 10, 2018 (the "Merger Agreement"), in exchange for a cash payment of $7.40 per share, without interest, subject to any required withholding of taxes (the "Offer Price"). Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 18:39 UTC | VIVUS INC VVUS · Entity 151460 | Tax withholdingCommon Stock | 43 | $5.63 | $242.09 |
DisclosureSEC source: 0001123292-18-000995 · edgar.xml · nonDerivative · entry 2 Roberts Eric W · CIK 0001576244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,160 F4 · shares: The reporting person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than by way of forfeiture to VIVUS, Inc. in order to cover estimated tax liability. F5 · price: The price reported for the securities is the market value on the business day immediately before September 15, 2018. F3 · balance_after: The number of shares beneficially owned following the reported transaction has been adjusted to reflect the Reverse Split (with fractional shares rounded up to the next whole number). Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 18:39 UTC | VIVUS INC VVUS · Entity 151460 | Exercise / conversionCommon Stock | 139 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-18-000995 · edgar.xml · nonDerivative · entry 1 Roberts Eric W · CIK 0001576244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,203 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On September 10, 2018, VIVUS, Inc. effected a 1-for-10 reverse stock split (the "Reverse Split"). Accordingly, 1,389 shares of common stock on a pre-Reverse Split basis were adjusted to 139 shares following the Reverse Split (with fractional shares rounded up to the next whole number). The shares of common stock relate to the previously disclosed restricted stock units that vested on September 15, 2018 and released on October 1, 2018. F2 · price: Restricted stock units converted into VIVUS, Inc. common stock on a 1-for-1 basis upon vesting. F3 · balance_after: The number of shares beneficially owned following the reported transaction has been adjusted to reflect the Reverse Split (with fractional shares rounded up to the next whole number). Read SEC document |
| September 15, 2018 Filed Sep 18, 2018 21:09 UTC | VIVUS INC VVUS · Entity 151460 | Exercise / conversionRestricted Stock Units · Derivative | 139 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-18-000964 · edgar.xml · derivative · entry 1 Roberts Eric W · CIK 0001576244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139 Underlying: Common Stock · 139 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On September 10, 2018, VIVUS, Inc. effected a 1-for-10 reverse stock split (the "Reverse Split"). Accordingly, 1,389 shares of common stock on a pre-Reverse Split basis was adjusted to 139 shares following the Reverse Split (with fractional shares rounded up to the next whole number). The shares of common stock will be released to the reporting person on a later date. F2 · derivative.exercise_price: Restricted stock units converted into VIVUS, Inc. common stock on a 1-for-1 basis upon vesting. F1 · shares: On September 10, 2018, VIVUS, Inc. effected a 1-for-10 reverse stock split (the "Reverse Split"). Accordingly, 1,389 shares of common stock on a pre-Reverse Split basis was adjusted to 139 shares following the Reverse Split (with fractional shares rounded up to the next whole number). The shares of common stock will be released to the reporting person on a later date. F3 · derivative.exercise_date: The restricted stock units vest according to the following schedule: 8/36ths of the total restricted stock units originally granted vested on May 15, 2016 and an additional 1/36th of the total restricted stock units originally granted vest on the 15th of each month thereafter, subject to the individual continuing to be a Service Provider (as defined in the VIVUS, Inc. 2010 Equity Incentive Plan) on the relevant vesting dates. F3 · derivative.expiration_date: The restricted stock units vest according to the following schedule: 8/36ths of the total restricted stock units originally granted vested on May 15, 2016 and an additional 1/36th of the total restricted stock units originally granted vest on the 15th of each month thereafter, subject to the individual continuing to be a Service Provider (as defined in the VIVUS, Inc. 2010 Equity Incentive Plan) on the relevant vesting dates. F1 · derivative.underlying_shares: On September 10, 2018, VIVUS, Inc. effected a 1-for-10 reverse stock split (the "Reverse Split"). Accordingly, 1,389 shares of common stock on a pre-Reverse Split basis was adjusted to 139 shares following the Reverse Split (with fractional shares rounded up to the next whole number). The shares of common stock will be released to the reporting person on a later date. F1 · balance_after: On September 10, 2018, VIVUS, Inc. effected a 1-for-10 reverse stock split (the "Reverse Split"). Accordingly, 1,389 shares of common stock on a pre-Reverse Split basis was adjusted to 139 shares following the Reverse Split (with fractional shares rounded up to the next whole number). The shares of common stock will be released to the reporting person on a later date. Read SEC document |
| August 15, 2018 Filed Aug 16, 2018 16:31 UTC | VIVUS INC VVUS · Entity 151460 | Exercise / conversionRestricted Stock Units · Derivative | 1,389 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-18-000933 · edgar.xml · derivative · entry 3 Roberts Eric W · CIK 0001576244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,778 Underlying: Common Stock · 1,389 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units converted into VIVUS, Inc. common stock on a 1-for-1 basis upon vesting. F3 · derivative.exercise_date: The restricted stock units vest according to the following schedule: 8/36ths of the total restricted stock units originally granted vested on May 15, 2016 and an additional 1/36th of the total restricted stock units originally granted vest on the 15th of each month thereafter, subject to the individual continuing to be a Service Provider (as defined in the VIVUS, Inc. 2010 Equity Incentive Plan) on the relevant vesting dates. F3 · derivative.expiration_date: The restricted stock units vest according to the following schedule: 8/36ths of the total restricted stock units originally granted vested on May 15, 2016 and an additional 1/36th of the total restricted stock units originally granted vest on the 15th of each month thereafter, subject to the individual continuing to be a Service Provider (as defined in the VIVUS, Inc. 2010 Equity Incentive Plan) on the relevant vesting dates. Read SEC document |
| August 15, 2018 Filed Aug 16, 2018 16:31 UTC | VIVUS INC VVUS · Entity 151460 | Tax withholdingCommon Stock | 438 | $0.63 | $275.94 |
DisclosureSEC source: 0001123292-18-000933 · edgar.xml · nonDerivative · entry 2 Roberts Eric W · CIK 0001576244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,632 F2 · shares: The reporting person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than by way of forfeiture to VIVUS, Inc. in order to cover estimated tax liability. Read SEC document |
| August 15, 2018 Filed Aug 16, 2018 16:31 UTC | VIVUS INC VVUS · Entity 151460 | Exercise / conversionCommon Stock | 1,389 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-18-000933 · edgar.xml · nonDerivative · entry 1 Roberts Eric W · CIK 0001576244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,070 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units converted into VIVUS, Inc. common stock on a 1-for-1 basis upon vesting. Read SEC document |
| July 15, 2018 Filed Jul 17, 2018 16:17 UTC | VIVUS INC VVUS · Entity 151460 | Exercise / conversionRestricted Stock Units · Derivative | 1,389 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-18-000865 · edgar.xml · derivative · entry 3 Roberts Eric W · CIK 0001576244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,167 Underlying: Common Stock · 1,389 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units converted into VIVUS, Inc. common stock on a 1-for-1 basis upon vesting. F3 · derivative.exercise_date: The restricted stock units vest according to the following schedule: 8/36ths of the total restricted stock units originally granted vested on May 15, 2016 and an additional 1/36th of the total restricted stock units originally granted vest on the 15th of each month thereafter, subject to the individual continuing to be a Service Provider (as defined in the VIVUS, Inc. 2010 Equity Incentive Plan) on the relevant vesting dates. F3 · derivative.expiration_date: The restricted stock units vest according to the following schedule: 8/36ths of the total restricted stock units originally granted vested on May 15, 2016 and an additional 1/36th of the total restricted stock units originally granted vest on the 15th of each month thereafter, subject to the individual continuing to be a Service Provider (as defined in the VIVUS, Inc. 2010 Equity Incentive Plan) on the relevant vesting dates. Read SEC document |
| July 15, 2018 Filed Jul 17, 2018 16:17 UTC | VIVUS INC VVUS · Entity 151460 | Tax withholdingCommon Stock | 439 | $0.77 | $338.03 |
DisclosureSEC source: 0001123292-18-000865 · edgar.xml · nonDerivative · entry 2 Roberts Eric W · CIK 0001576244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,681 F2 · shares: The reporting person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than by way of forfeiture to VIVUS, Inc. in order to cover estimated tax liability. Read SEC document |
| July 15, 2018 Filed Jul 17, 2018 16:17 UTC | VIVUS INC VVUS · Entity 151460 | Exercise / conversionCommon Stock | 1,389 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-18-000865 · edgar.xml · nonDerivative · entry 1 Roberts Eric W · CIK 0001576244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,120 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units converted into VIVUS, Inc. common stock on a 1-for-1 basis upon vesting. Read SEC document |
| June 15, 2018 Filed Jun 19, 2018 16:18 UTC | VIVUS INC VVUS · Entity 151460 | Exercise / conversionRestricted Stock Units · Derivative | 1,389 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-18-000821 · edgar.xml · derivative · entry 3 Roberts Eric W · CIK 0001576244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,556 Underlying: Common Stock · 1,389 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units converted into VIVUS, Inc. common stock on a 1-for-1 basis upon vesting. F3 · derivative.exercise_date: The restricted stock units vest according to the following schedule: 8/36ths of the total restricted stock units originally granted vested on May 15, 2016 and an additional 1/36th of the total restricted stock units originally granted vest on the 15th of each month thereafter, subject to the individual continuing to be a Service Provider (as defined in the VIVUS, Inc. 2010 Equity Incentive Plan) on the relevant vesting dates. F3 · derivative.expiration_date: The restricted stock units vest according to the following schedule: 8/36ths of the total restricted stock units originally granted vested on May 15, 2016 and an additional 1/36th of the total restricted stock units originally granted vest on the 15th of each month thereafter, subject to the individual continuing to be a Service Provider (as defined in the VIVUS, Inc. 2010 Equity Incentive Plan) on the relevant vesting dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.